CRVS logo

CRVS
Corvus Pharmaceuticals Inc

6,725
Mkt Cap
$1.35B
Volume
1.27M
52W High
$26.95
52W Low
$3.17
PE Ratio
-31.77
CRVS Fundamentals
Price
$16.08
Prev Close
$16.02
Open
$16.11
50D MA
$15.93
Beta
1.47
Avg. Volume
1.35M
EPS (Annual)
-$0.5372
P/B
19.62
Rev/Employee
$0.00
$552.22
Loading...
Loading...
News
all
press releases
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen raised shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2% - Here's Why
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 10.2% - What's Next...
MarketBeat·3d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 9.5% - What's Next?
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 9.5% Higher - Here's What Happened...
MarketBeat·5d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group
The Goldman Sachs Group raised shares of Corvus Pharmaceuticals to a "strong-buy" rating in a research note on Friday...
MarketBeat·8d ago
News Placeholder
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside
Goldman Sachs initiated coverage of Corvus with a ‘Buy’ rating and $40 price target, according to The Fly.
Stocktwits·9d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's What Happened
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - What's Next...
MarketBeat·9d ago
News Placeholder
This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says
Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according to Goldman Sachs...
CNBC: Top News·9d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 4.3% - Should You Sell?
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 4.3% - Here's What Happened...
MarketBeat·11d ago
News Placeholder
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six h...
MarketBeat·21d ago
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below Fifty Day Moving Average - What's Next?
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below Fifty Day Moving Average - What's Next...
MarketBeat·25d ago
<
1
2
...
>

Latest CRVS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.